July 15, 2017

Gilead Sciences Business Development at a Glance

Of the top 10 pharmaceutical companies by revenue in 2017, 9th is Gilead Sciences. (source) Gilead makes an interesting subject for business development professionals, as they are cash heavy and must develop or acquire new blockbuster drugs before current revenue-producers wane or their patent protection expires.

Gilead Stock

Gilead Sciences, Inc.
Company Type: Large Pharma
Region: United States, Worldwide
Cash Position: $9809M USD
Therapeutic Focus: HIV/AIDS, Liver Diseases, Hematology/Oncology, Inflammation/Respiratory, Infectious Diseases

Deal Activity

Gilead Data

Figure 1. Gilead Sciences, Inc. In-Licensing Deals and Acquisitions, 2012 through Present (July 2017)

Recent Deal Highlights:

ACQUISITION OF NIMBUS THERAPEUTICS ACETYL-COA CARBOXYLASE (ACC) INHIBITOR PROGRAM

Total Size: $1200M | Upfront: $400M | Therapeutic Area: Liver Disease | Date: April 2016
PRESS |SEC

GLOBAL PARTNERSHIP WITH GALAPAGOS TO DEVELOP FILGOTINIB JAK1 INHIBITOR

Total Size: $2075M  | Upfront: $300M License Fee + $425 Equity Investment | Therapeutic Area: Inflammation / Respiratory | Date: December 2015
PRESS | SEC

ACQUISITION OF EPITHERAPEUTICS LIBRARY OF FIRST-IN-CLASS, SELECTIVE SMALL MOLECULE INHIBITORS OF EPIGENETIC REGULATION OF GENE TRANSCRIPTION

Total Size: $65M | Therapeutic Area: Oncology | Date: May 2015
PRESS | SEC

R&D PIPELINE

Gilead Pipeline

Figure 2. Gilead Sciences, Inc. R&D Pipeline at present (July 2017)

Products from Recent Deals:

ACQUIRED NIMBUS THERAPEUTICS ACC INHIBITOR PROGRAM
Disease Area: Liver Disease | Status: NASH Phase II

GALAPAGOS PARTNERED FILGOTINIB JAK1 INHIBITOR
Disease Area: Inflammation / Respiratory | Status: Rheumatoid Arthritis Phase III | Crohn's Disease Phase III | Ulcerative Colitis Phase III | Active Non-Infectious Uveitis Phase II

ACQUIRED EPITHERAPEUTICS
Disease Area: Oncology | The status of these acquired pre-clinical assets is unclear.

BUSINESS DEVELOPMENT TEAM

Business profiles tailored to your asset.